Can CCL19 Predict Chronic Lyme Disease Symptoms?

Researchers are studying whether CCL19 may help identify patients at risk for persistent Lyme symptoms.
Elevated immune markers may reflect ongoing inflammation after treatment.
CCL19 has been linked to Post-Treatment Lyme Disease Syndrome (PTLDS).

T-cell chemokines may play an important role in the development of persistent symptoms following Lyme disease. Research has identified CCL19 as a potential immune marker associated with Post-Treatment Lyme Disease Syndrome (PTLDS).

Researchers have increasingly explored whether immune biomarkers can help explain why some patients recover fully after Lyme disease while others continue to experience fatigue, pain, brain fog, and neurologic symptoms.

What Is CCL19?

CCL19 is a chemokine involved in regulating immune responses, particularly T-cell activity and inflammatory signaling.

In early Lyme disease, CCL19 levels typically rise and then return to normal following treatment in most patients.

When CCL19 Remains Elevated

In approximately 14% of patients, CCL19 levels remain elevated despite standard antibiotic therapy.

These individuals were found to have a significantly higher risk of developing PTLDS.

Patients with CCL19 levels above a defined threshold had more than a 12-fold increased risk of persistent symptoms at 6 to 12 months.

This finding suggests that persistent immune activation may contribute to chronic Lyme disease symptoms in some patients.

What Is PTLDS?

Post-Treatment Lyme Disease Syndrome is characterized by ongoing symptoms following treatment for Lyme disease.

Common symptoms may include:

• Fatigue
• Musculoskeletal pain
• Cognitive difficulties
• Brain fog
• Reduced functional capacity

These symptoms can significantly affect quality of life and daily functioning.

What Might Elevated CCL19 Mean?

Elevated CCL19 levels may reflect an ongoing immune response after Lyme disease.

Possible explanations include:

• Persistent bacterial antigens
• Immune system dysregulation
• An autoimmune component
• In some cases, possible persistence of infection

These mechanisms remain areas of ongoing investigation.

Why Cytokines and Chemokines Matter in Lyme Disease

Cytokines and chemokines help regulate the immune response to infection. Researchers are studying whether persistent immune signaling after Lyme disease may contribute to fatigue, pain, brain fog, and neurologic symptoms in some patients.

CCL19 is one example of a chemokine that may reflect ongoing immune activation following treatment.

Interest in cytokines and chemokines has grown as investigators explore why some patients recover fully while others continue to experience persistent symptoms after standard therapy.

Links to Other Neurologic Conditions

Elevated chemokines, including CCL19 and CXCL13, have also been observed in other inflammatory neurologic conditions such as multiple sclerosis and neuroborreliosis.

This overlap suggests that similar immune pathways may be involved across different neuroinflammatory diseases.

Implications for Care

Understanding immune markers like CCL19 may eventually help identify Lyme disease patients at higher risk for persistent symptoms.

Management strategies discussed in the literature include:

• Symptom-based treatment for pain and fatigue
• Behavioral and cognitive interventions
• Neurologic evaluation in selected cases
• Careful clinical follow-up over time

Some clinicians have explored additional antibiotic therapy in certain situations, although this approach remains an area of ongoing study.

Clinical Perspective

CCL19 provides insight into the immune response associated with Lyme disease and its chronic manifestations.

While not yet a routine clinical test, it highlights the growing recognition that persistent symptoms after Lyme disease may involve measurable biologic and immune system changes.

CCL19 is not currently used as a standard diagnostic test for Lyme disease. Instead, it is being studied as a research biomarker that may help identify patients at higher risk for persistent symptoms following treatment.

Researchers at the Johns Hopkins Lyme Disease Research Center found that some patients with persistently elevated CCL19 levels after treatment were more likely to later develop ongoing symptoms associated with PTLDS.

Patients may benefit from understanding persistent Lyme disease mechanisms, reviewing testing limitations, and considering neurologic Lyme disease when symptoms continue.

Frequently Asked Questions

What is CCL19 in Lyme disease?

CCL19 is an immune signaling molecule that has been associated with persistent symptoms following Lyme disease treatment.

Can CCL19 predict chronic Lyme disease symptoms?

Studies suggest elevated CCL19 levels may identify patients at increased risk for PTLDS and persistent symptoms.

Does a high CCL19 level mean infection is still present?

Not necessarily. Elevated levels may reflect immune activity, inflammation, or other biologic mechanisms that are still being studied.

Is CCL19 testing routinely used in Lyme disease care?

No. CCL19 is currently considered a research biomarker rather than a standard clinical test.

---

Dr. Daniel Cameron, MD, MPH
Lyme disease clinician with over 30 years of experience and past president of ILADS.

Symptoms • Testing • Coinfections • Recovery • Pediatric • Prevention